Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experience. by Schindewolf, Marc
Res Pract Thromb Haemost. 2019;3:9–11.	 	 	 | 	9wileyonlinelibrary.com/journal/rth2
 
Received:	15	October	2018  |  Accepted:	4	November	2018
DOI: 10.1002/rth2.12169
C O M M E N T A R Y
Fondaparinux in heparin- induced thrombocytopenia:  
A decade’s worth of clinical experience
Marc Schindewolf MD
Swiss	Cardiovascular	Center,	Division	of	Vascular	Medicine,	University	Hospital	Bern,	Bern,	Switzerland
Correspondence
Marc	Schindewolf,	Swiss	Cardiovascular	Center,	Division	of	Vascular	Medicine,	University	Hospital	Bern,	Bern,	Switzerland.
Email: marc.schindewolf@insel.ch 
Fondaparinux	 is	 an	 antithrombin-	dependent,	 synthetic	 anti-	factor	
Xa-	inhibitor	that	is	used	off-	label	as	an	alternative	anticoagulant	in	
the	 treatment	 of	 life-	threatening	 immune	 heparin-	induced	 throm-
bocytopenia	 (HIT).	 In	 their	 systematic	 review,	Dr.	 Linkins	 and	 col-
leagues	have	summarized	what	is	currently	known	on	fondaparinux’	
safety	and	efficacy	when	used	in	patients	with	diagnosed	and	sus-
pected	heparin-	induced	thrombocytopenia.1	The	authors	have	per-
formed	an	extensive	systematic	literature	search	on	data	that	have	
been	published	between	2006	and	2017.
The	presented	data	are	important	because	the	current	approved	
alternative	anticoagulants	 for	 treating	 this	condition	have	clear	 lim-
itations:	 (i)	 the	factor	Xa-	inhibitor	danaparoid	 is	not	available	 in	 the	
United	States	and	has	been	subject	to	world-	wide	shortages	repeat-
edly2;	(ii)	use	of	the	thrombin	inhibitor	argatroban	is	limited	in	patients	
with	hepatic	insufficiency	and	aPTT-	and	INR-	confounding	may	occur	
in	various	clinical	settings,	eg,	disseminated	intravascular	coagulation,	
during	heparin	therapy,	transition	to	vitamin	K	antagonist	treatment3; 
(iii)	outpatient	use	of	argatroban	and	bivalirudin	is	precluded	because	
these	drugs	require	continuous	 IV	 infusion	and	frequent	 laboratory	
monitoring;	(iv)	argatroban,	bivalirudin,	and	danaparoid	use	is	expen-
sive, at least in some jurisdictions4;	and	(v)	last	but	not	least,	the	re-
combinant	hirudin	 lepirudin	 is	not	available	on	the	market	anymore	
since 2012.2
However,	the	main	shortcoming	of	fondaparinux	use	in	HIT	is	still	
that	there	has	not	been	any	randomized-	controlled	trial	to	date	and	
authorities’	approval	has	not	been	granted	formally.
In	order	 to	 increase	 the	validity	of	 their	 study,	Dr.	 Linkins	 and	
colleagues	 have	 applied	 strict	 inclusion	 and	 exclusion	 criteria	 (ie,	
fondaparinux	 as	 primary	 anticoagulant	 with	 no	 other	 alternative	
anticoagulant	 allowed	 for	 >24	hours;	 sufficient	 case	 number	 (≥5	
patients);	 laboratory	 confirmation	 of	HIT	 (serotonin-	release	 assay,	
heparin-	induced	platelet	activation	assay,	or	enzyme-	linked	 immu-
nosorbent	assay),	in	combination	with	clinical	symptoms	consistent	
with	 at	 least	 an	 intermediate	 pretest	 probability	 for	 HIT	 (eg,	 4Ts	
score5).	These	rigid	patient	selection	criteria	are	pivotal	when	draw-
ing	conclusions	on	general	applicability	when	there	are	no	high	qual-
ity	data	from	RCTs.
The	question	is	if	this	has	prevented	or	will	prevent	physicians	in	
daily	practice	from	applying	the	drug	in	patients	with	suspected	or	
diagnosed	heparin-	induced	thrombocytopenia?
The	answer	is	no,	because	the	users	have	already	“voted	with	
their	 feet”	 in	 favor	 of	 fondaparinux6	 with	 off-	label	 use	 rates	 of	
up	 to	50%	even	 in	patients	with	high	clinical	pretest	probability	
of	HIT.7,8	This—besides	reports	on	successful	fondaparinux	use	in	
HIT—may	have	been	triggered	by	low	therapy	cost	as	compared	to	
approved	alternative	anticoagulants,	being	the	main	cost-	drivers	
in	therapy,4	the	ease	of	subcutaneous	administration	of	the	drug,	
and	the	lack	of	need	for	routine	laboratory	monitoring	and	dose	
adjustment.1
Different	 mechanisms	 of	 action,	 eg,	 direct	 oral	 factor	 Xa	 or	
thrombin	inhibition,	could	overcome	the	rare,	but	potential	limitation	
of	fondaparinux	to	cause	HIT	itself,9	and	direct	oral	anticoagulants	
have been widely available. However, the authors of this review have 
already	reported	the	same	difficulties	of	 identifying	and	recruiting	
HIT	patients	for	a	robust	prospective	trial	using	direct	oral	antico-
agulants	 that	 already	 apply	 for	 fondaparinux.10	 Together	with	 the	
manufacturer’s	lack	of	interest	in	investing	into	research	to	expand	
indications	this	will	pose	the	same	problem	as	already	observed	with	
fondaparinux:	 there	might	 be	 no	RCTs	 of	 high	 quality	 available	 in	
the	future	and	gathering	clinical	experience	with	direct	oral	antico-
agulants	to	the	same	extent	as	for	fondaparinux	 is	expanding	only	
slowly.	 Thus,	 the	 data	 presented	 by	 the	 authors	 of	 a	 comparable	
efficacy	 in	 preventing	 thromboembolic	 complications	 and	 safety	
with	respect	to	bleeding	complications,	represent	the	largest	body	
of	evidence	to	date	for	an	off-	label	alternative	anticoagulant	in	the	
treatment	of	HIT.
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The	 authors’	 compilation	 of	 clinical	 data	 on	 HIT	 management	
with	 fondaparinux	might	 help	 to	 harmonize	 current	 treatment	 rec-
ommendations.	Looking	at	the	different	guideline	recommendations	
from	various	professional	or	governmental	associations	reveals	that	
these	differ	not	only	 in	methodological	 aspects	but	as	well	 in	 their	
conclusions drawn.11	While	some	guidelines	recommend	the	use	of	
fondaparinux,12–14	 fondaparinux	carries	 a	 level	2C	 recommendation	
from	the	American	College	of	Chest	Physicians	 (ACCP).15 However, 
ACCP	 held	 out	 the	 prospect	 of	 readjusting	 their	 recommendations	
once	more	 clinical	 evidence	 has	 emerged.	 The	 data	 of	 Linkins	 and	
colleagues	might	now	contribute	 to	start	 this	discussion	and	to	put	
current	fondaparinux	off-	label	practice	on	a	safer	medico-	legal	level	
for	the	treating	physicians.	Advocacy	in	favor	of	fondaparinux	already	
when	 underlying	 HIT	 is	 suspected	 and	 thereby	 “legalizing”	 its	 use	
might	face	the	clinical	problem	that	HIT	diagnosis	and	therapy	is	often	
delayed.16	However,	one	must	take	into	account	that	“true”	HIT	is	still	
rare	compared	to	the	number	of	patients	with	HIT	suspicion	and	that	
HIT	is	often	overdiagnosed	and	overtreated.17,18	Thus,	fondaparinux	
use	will	mostly	concern	patients	with	HIT	suspicion.
Among	numerous	patients	with	suspected	or	diagnosed	HIT	who	
were	treated	with	fondaparinux,	dosing	was	inconsistent.8,19,20	This	will	
remain	a	future	challenge	for	research	against	the	background	of	clin-
ical	HIT	probability,	thromboembolic	complications,	and	bleeding	risk.
ADDENDUM
The	release	of	the	American	Society	of	Hematology	(ASH)	2018	guide-
lines	for	management	of	venous	thromboembolism:	heparin-induced	
thrombocytopenia	 (HIT),21	 after	 this	writing,	 recommended	 the	 use	
of	fondaparinux	in	the	treatment	of	acute	HIT	with	thromboembolic	
complications.	Despite	the	reference	to	the	very	low		certainty	in	the	
evidence	about	effects,	 no	preference	 is	 suggested	 for	non-heparin	
anticoagulants	 over	 fondaparinux	 in	 these	 guidelines.	 However,	 the	
choice	of	agent	may	be	 influenced	by	drug	factors	 (availability,	cost,	
ability	to	monitor	the	anticoagulant	effect,	route	of	administration,	and	
half-life),	patient	factors	(kidney	function,	liver	function,	bleeding	risk,	
clinical	stability,	and	need	for	urgent	procedures),	and	experience	of	
the clinician.
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